Substance / Medication

Furazolidone

Overview

Active Ingredient
furazolidone
RxNorm CUI
4601

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

7
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
What are the immunopharmacological effects of furazolidone? A systematic review.
Feitosa Ivan Brito, Mori Bruno, Santos Ana Paula de Azevedo Dos et al. · Immunopharmacol Immunotoxicol · 2021
PMID: 34570666Meta-Analysis
Safety of furazolidone-containing regimen ininfection: a systematic review and meta-analysis.
Ji Chao-Ran, Liu Jing, Li Yue-Yue et al. · BMJ Open · 2020
PMID: 33077561Meta-AnalysisFull text (PMC)
Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis.
Zhuge Liya, Wang Youhua, Wu Shuang et al. · Helicobacter · 2018
PMID: 29480532Meta-Analysis
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Qiao Chen, Li Yueyue, Liu Jing et al. · J Gastroenterol Hepatol · 2021
PMID: 33691344RCT
[Efficacy of triple versus quadruple furazolidone-based eradication regimens for Helicobacter pylori infection].
Lü Zhifa, Xie Yong, Lü Nonghua et al. · Zhonghua Yi Xue Za Zhi · 2014
PMID: 24762683RCT
Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial.
Hajaghamohammadi Aliakbar, Safiabadi Tali Seyyed Hossein, Samimi Rasoul et al. · Glob J Health Sci · 2014
PMID: 25560342RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Furazolidone (substance)
SNOMED CT
91314000
UMLS CUI
C0016855
RxNorm CUI
4601

Clinical Data

This intervention maps to 8 entities in the Ltrl knowledge graph.

8
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.